133 related articles for article (PubMed ID: 31250729)
41. The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplants.
Murphy NM; Diviney M; Szer J; Bardy P; Grigg A; Hoyt R; King-Kallimanis B; Holdsworth R; McCluskey J; Tait BD
Biol Blood Marrow Transplant; 2012 May; 18(5):722-30. PubMed ID: 21920473
[TBL] [Abstract][Full Text] [Related]
42. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
[TBL] [Abstract][Full Text] [Related]
43. Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism.
Gammon DC; Bhatt MS; Patel B; Anderson M; Van Horn A; Glantz MJ
J Oncol Pharm Pract; 2008 Sep; 14(3):153-6. PubMed ID: 18719070
[TBL] [Abstract][Full Text] [Related]
44. MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk.
Juster-Switlyk K; Smith AG; Kovacsovics T; Stephens D; Glenn M; Palmer CA; Quigley EP; Kolb N
Neurology; 2017 Feb; 88(6):603-604. PubMed ID: 28062724
[No Abstract] [Full Text] [Related]
45. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer.
Cheng KK
Eur J Cancer Care (Engl); 2008 May; 17(3):306-11. PubMed ID: 18419635
[TBL] [Abstract][Full Text] [Related]
46. Methotrexate pulmonary toxicity.
Lateef O; Shakoor N; Balk RA
Expert Opin Drug Saf; 2005 Jul; 4(4):723-30. PubMed ID: 16011450
[TBL] [Abstract][Full Text] [Related]
47. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
Zheng MM; Yue LJ; Chen XW; Wen FQ; Li CG; Yang CL; Xie C; Ding H
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar; 15(3):201-6. PubMed ID: 23498762
[TBL] [Abstract][Full Text] [Related]
48. Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.
Choi YJ; Park H; Lee JS; Lee JY; Kim S; Kim TW; Park JS; Kim JE; Yoon DH; Suh C
Hematol Oncol; 2017 Dec; 35(4):504-509. PubMed ID: 27781293
[TBL] [Abstract][Full Text] [Related]
49. Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia.
Diaz J; Thomas MB; Paz-Pabon C; Hernandez E
J Reprod Med; 2012; 57(9-10):411-4. PubMed ID: 23091988
[TBL] [Abstract][Full Text] [Related]
50. Acute hypokalemic tetraparesis induced by intravenous methotrexate.
Thuss-Patience PC; Peters U; Jurkat-Rott K; Pink D; Kretzschmar A; Dörken B; Reichardt P
J Clin Oncol; 2003 May; 21(9):1896-7. PubMed ID: 12721279
[No Abstract] [Full Text] [Related]
51. Histological Effect of Methotrexate and Folinic Acid on Oral Epithelium of Albino Rats.
Ahmad A; Kazi MS
J Coll Physicians Surg Pak; 2016 Jun; 26(6):455-8. PubMed ID: 27353978
[TBL] [Abstract][Full Text] [Related]
52. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
[TBL] [Abstract][Full Text] [Related]
53. Repeated Episodes of Leukoencephalopathy after High-dose Methotrexate in a Child with Acute Lymphoblastic Leukemia.
Tsao TF; Chao YH
Indian Pediatr; 2017 Feb; 54(2):159. PubMed ID: 28285295
[No Abstract] [Full Text] [Related]
54. Genetic markers that could influence clinical decision making during treatment with methotrexate.
Esperon P; Giletti A
Pharmacogenomics; 2020 Jun; 21(8):505-507. PubMed ID: 32342716
[No Abstract] [Full Text] [Related]
55. Methotrexate-induced periorbital radiation recall.
Kiel PJ; Jones KL
Ann Pharmacother; 2011 Jan; 45(1):133. PubMed ID: 21205951
[No Abstract] [Full Text] [Related]
56. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of Parenteral Glutamine on Methotrexate-induced Oral Mucositis in Children with Acute Lymphoblastic Leukemia.
Chang YH; Yu MS; Wu KH; Hsu MC; Chiou YH; Wu HP; Peng CT; Chao YH
Nutr Cancer; 2017 Jul; 69(5):746-751. PubMed ID: 28569624
[TBL] [Abstract][Full Text] [Related]
58. [Therapeutic drug monitoring of methotrexate after its administration in high-dose protocols].
Le Guellec C; Blasco H; Benz I; Hulin A;
Therapie; 2010; 65(3):163-9. PubMed ID: 20699066
[TBL] [Abstract][Full Text] [Related]
59. High-dose methotrexate for primary CNS lymphoma in the elderly.
Ng S; Rosenthal MA; Ashley D; Cher L
Neuro Oncol; 2000 Jan; 2(1):40-4. PubMed ID: 11302253
[TBL] [Abstract][Full Text] [Related]
60. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
